Dec 18, 2009 | Laboratory News, Laboratory Pathology
Researchers say Mobidiag’s microarray-based diagnostic test technology looks promising
There’s a new DNA-based microarray platform that could speed identification of blood-borne pathogens. By allowing clinical laboratories to deliver test results in just 18 hours, use of this new microarray could improve early detection and management of sepsis patients.
In a study headed by Päivi Tissari, M.D., of the Division of Clinical Microbiology, Helsinki University Hospital Laboratory in Finland, the Prove-it sepsis assay, manufactured by Helsinki-based Mobidiag, demonstrated 94.7% clinical sensitivity, 98.8% specificity, along with 100% sensitivity and specificity for methicillin-resistant Staphylococcus aureus bacteremia. The conventional process of growing a culture—the medical laboratory’s gold standard—typically takes between one to three days to become positive and two more days to identify the bacteria and their antibiotic sensitivity patterns. Mobidiag’s Prove-it sepsis assay returns results in only 18 hours.
(more…)
Aug 12, 2009 | Digital Pathology, Laboratory News, Laboratory Pathology
Use of digital pathology imaging allows both specialists to jointly review cases
In a pioneering effort at The University of Kansas, a radiologist and a pathologist are working side by side to review each other’s primary images and issue an integrated diagnostic report for breast cancer patients. The big surprise from this groundbreaking collaboration is a measurable improvement in diagnostic accuracy, leading to improved patient outcomes.
By reaching across the traditional silos that separate the daily practice of radiology from the daily practice of pathology, these two specialists have demonstrated that the concept of diagnostic integration of in vivo (imaging) and in vitro (pathology) diagnostics can demonstrably improve patient care. In part, this happens because of improved concordance in the reports issued by the radiologist and the pathologist.
(more…)
Jun 3, 2009 | Laboratory News, Laboratory Pathology
Latest-generation DNA sequencing technology helped scientists achieve this feat
This spring, a particularly interesting milestone on the road to genetic medicine was achieved. The genome of Neanderthal man has been sequenced at the 1X level. It is a remarkable accomplishment by scientists from both the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, and 454 Life Sciences Inc. , a division of Roche Holdings.
The final Neanderthal draft sequence is made up of three billion bases of Neanderthal DNA. This represents an estimated two-thirds of the entire genome. A research team has been assembled to evaluate and analyze the Neanderthal genome. Their findings may be published by the end of the year.
(more…)
May 30, 2007 | Laboratory Management and Operations, Laboratory News, Laboratory Operations
On Wednesday of last week, Prof. Dr. Erich R. Reinhardt, President and CEO of Siemens Medical Solutions (NYSE: SI), traveled from Germany to the United States to deliver an address on how Siemens expects to integrate in vivo (imaging) diagnostics, in vitro diagnostics (IVD), and informatics to create new value streams in healthcare. This is a topic of high interest within the laboratory community, ever since Siemens spent billions to buy a major presence in the lab testing marketplace last year with its acquisitions of DPC and Bayer Diagnostics.
Reinhardt was at the headquarters of Siemens Medical Solutions Diagnostics in Tarrytown, New York, to speak to a group of healthcare journalists from Europe and the United States. After Reinhardt’s address, Siemens Medical Solutions Diagnostics CEO, Tony Bihl gave a presentation that was followed by a panel of three outside experts, including Dark Daily Editor Robert L. Michel, Richard G. Friedberg, M.D., Ph.D., Chairman of Pathology at Bay State Medical Center in Springfield, Massachusetts, and Paul R. Billings, M.D., Ph.D., Vice President and Senior Geneticist, Strategic Planning at Laboratory Corporation of America.
Reinhardt’s message was clear and consistent with earlier pronouncements on this topic by senior Siemens executives. “New technologies in both imaging and in vitro diagnostics provide useful clinical knowledge for physicians,” he said. “This allows clinicians to diagnose disease earlier and with more precision. At the same time, these technologies generate increasing quantities of data. That creates the opportunity to use information technology in several ways to further increase value and enhance work flow.”
One application of information technology is to better analyze the primary data generated by an imaging procedure or a molecular laboratory test. “Smart software can analyze the ever-growing quantities of raw data and increase the sensitivity and precision of the clinical diagnosis,” explained Reinhardt. “The second, and equally valuable, contribution of information technology is to streamline clinical and operational processes in the healthcare continuum.”
Two products form the cornerstone of Siemens’ informatics strategy: Soarian and syngo. Reinhardt discussed how these software systems can be used by hospitals and healthcare providers to manage clinical work flow and operational workflow. Reinhardt noted that there are 50 such Sorian “integrated work flow solutions” in active use at 18 locations worldwide. He specifically mentioned Chester County Hospital of West Chester, Pennsylvania, which was so effective using this approach to redesign work flow that it won the “2006 North American Global Excellence Business Process Management (BPM) and Workflow Award” from the Workflow And Reengineering International Association (WARIA). One laboratory-related success at Chester Hospital was improvements in infection control that lead to a reduction in cost per case of $7,000.
One major insight from the presentations by Reinhardt and Bihl is that Siemens does not, at least in the short term, predict that some type of spectacular breakthrough or market-shaking innovation will result from its efforts to integrate imaging, in vitro diagnostics, and informatics. Rather, Siemens Medical Solutions is taking deliberate steps to integrate these three different technology areas to achieve two primary objectives. First, to improve clinical outcomes by enhancing the knowledge and clinical efficiency that these technologies deliver to physicians. Second, to contribute to efficiencies in operational work flow.
However, there could be a wild card to this effort. Siemens is the first major player in imaging to acquire and operate a major IVD manufacturing business. As Siemens’ researchers, engineers, and scientists involved in imaging and IVD manufacturing now start to meet regularly and look for specific opportunities to combine and integrate molecular technologies in imaging and laboratory testing, there is a strong possibility that these teams will find new and useful molecular markers that can be utilized by in vivo and in vitro procedures in complementary ways.
Dark Daily will be tracking these developments. Currently Siemens has a head start in the IVD manufacturing business over its major competitor. But when General Electric (NYSE: GE) becomes the owner of Abbott Diagnostics later this year, that will certainly intensify competition between these two healthcare corporations.
Related Information
The Chester County Hospital Wins Prestigious Business Process Management and Workflow Award
2006 Winners Announced for Excellence in BPM & Workflow Global Awards
Prof. Dr. Erich Reinhardt
Newt Gingrich and Siemens Medical CEO Erich Reinhardt Share Insight on the Future of Healthcare; Results of Opinion Leader Survey Will Be Revealed
Mar 22, 2007 | Uncategorized
Across the laboratory industry, there is keen curiosity about how imaging giants Siemens and General Electric plan to integrate in vitro diagnostics with in vivo diagnostics. Executives from both companies have not been detailed in their public statements about how integration of these two medical disciplines is likely to occur. But recently the opportunity presented itself for me to learn more about this subject.
Last week, I was privileged to co-chair a laboratory management meeting conducted by Siemens Medical Solutions Diagnostics in William Shakespeare’s home town of Stratford-upon-Avon, England. This was the third annual Process Management Meeting Siemens has produced for its laboratory customers in the United Kingdom. My co-chair was David Ricketts, Laboratory Manager at North Middlesex University Hospital in London, England.
One session at this meeting was targeted specifically at the topic of integrating in vitro and in vivo diagnostics. In a point/counterpoint discussion, Ricketts challenged Nico Arnold, the newly-appointed Head of Europe for Siemens Medical Solutions Diagnostics, to lay out the company’s strategy and give everyone in the meeting a better understanding of how Siemens’ intends to proceed to achieve integration of these two diagnostic disciplines.
Nico Arnold’s message was simple and clear. “Going forward, laboratory customers of Siemens will see a continued commitment to both the latest in lab test technology and a high level of value-added service,” he stated. “With its recent acquisitions, Siemens has become the world’s largest player in immunoassays and is one of the top three largest in vitro diagnostics (IVD) manufacturers globally. Siemens fully intends to be at the forefront of laboratory medicine, just as it is a leader in radiology and imaging.”
Arnold then emphasized that integration of laboratory medicine and radiology services can only be successful so long as Siemens maintains state-of-the-art technology. It will be the intersection of these evolving technologies that will create opportunities to integrate the two disciplines, thus delivering increased value to physicians. With its laboratory customers in the United Kingdom (UK), Siemens Medical Solutions Diagnostics was consistent in its message that integration will be an ongoing, but evolutionary, strategy within the company.
Lab managers and pathologists in the United States will also be interested in several other developments revealed at Siemens’ process management meeting. Just as in this country, UK laboratory leaders are taking active steps to improve operational performance, streamline workflow, and use quality management principles to raise quality and service even while reducing cost and eliminating waste.
For example, the laboratory of John Radcliffe Hospital in Oxford, England (associated with Oxford University School of Medicine) has reduced average test turnaround times using process re-engineering and new instrumentation arrangements. Richard Taylor, BSc, Ph.D., FRCPath, a Consultant Clinical Scientist at the laboratory, described the management initiatives which achieved those outcomes.
Lean, Six Sigma, benchmarking, and best practices were also discussed in detail and in multiple presentations. Like in the United States, laboratory administrators in the United Kingdom are willing to use a variety of new management approaches and methods.
One interesting statistic illustrates the scale of the challenge in the United Kingdom. During his presentation on using Lean principles to improve laboratory workflow and quality, Tony Currell, CSci, FIBMS, the Clinical Biochemistry Service Manager at St. Helens and Knowsley NHS Acute Trust in Merseyside, England, showed a slide that tracked the number of medical technologists in the United Kingdom. Since 1990, that number, about 20,000, has remained virtually unchanged for 17 years. Yet, over that same period, there has been a steady increase in both the number of lab tests on the menu and the volume of laboratory specimens tested. These facts demonstrate how the laboratory profession has managed to sustain laboratory services by using automation, new technology, and quality management methods to squeeze every bit of productivity out of laboratory resources.
Your travelling Dark Daily Editor,
Robert L. Michel
P.S. For those of you keenly interested in how laboratory medicine and radiology is destined become an integrated service, there will be an opportunity to get insights into Siemens’ plans and strategies at the upcoming Executive War College in Miami on May 10-11, 2007. Dave Hickey, Vice President of Strategic Marketing and Planning, Siemens Medical Solutions Diagnostics, Tarrytown, New York, will speak on “Full Service Diagnostics: The Coming Convergence of Imaging, Informatics, and In Vitro Diagnostics (IVD). You can access the full details using the links below. Take action today and join us in Miami.
Early-Bird Discount Registration now available online
Visit http://www.executivewarcollege.com
Download Full Program Agenda
You can:
1. Register ONLINE right now; or,
2. Call 800-560-6363. Our friendly staff can register you quickly and easily, as well as answer any questions you may have.
